Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 115

  • 96

  • 28

  • 27

  • 26

  • 18

  • 13

  • 13

  • 8

  • 8

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

Funder: National Cancer Institute

Funding period
USD 411 K
Funding amount
Abstract
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma Bladder cancer is the ninth most common cancer worldwide and the fourth most common cancer in men. Despite intensive multi-modality therapy, approximately 50% of patients with muscle-invasive disease develop distant metastases and historically such patients had little hope of long-term survival. The development of immune checkpoint inhibitors is the most significant therapeutic advance in bladder cancer in three decades and the development of these agents have provided renewed hope to many patients with previously incurable metastatic disease. Anti-PD1/PD-L1 antibodies can induce durable complete responses in patients with metastatic bladder cancer with several immune checkpoint inhibitors are now FDA-approved for this indication. However, the majority of patients with metastatic urothelial cancers do not benefit from immune checkpoint blockade and some patients who initially respond later develop acquired resistance. The biologic basis for innate and acquired resistance to immune checkpoint blockade in urothelial cancer remains poorly defined. Urothelial cancers display a wide spectrum of variant morphologies that often co-exist within individual tumors. We have shown that this morphologic heterogeneity is often associated with intra-tumoral mutational heterogeneity. The current proposal is based upon preliminary data indicating that morphologic heterogeneity in bladder cancer is associated with genomic and immune heterogeneity and is predictive of a worse response to atezolizumab (an anti-PD-L1 inhibitor). Three aims are proposed. In Aim 1, we will perform integrated histologic, genomic and immune analyses of paired, macro-dissected, morphologically distinct areas from morphologically heterogeneous tumors from patients treated with immune checkpoint blockade to define the prevalence and extent of intratumoral genetic and immune heterogeneity. In Aim 2, these tissue profiling studies will be integrated with detailed clinical and patients response data to define the role of pre-existent histologic, genomic and immune heterogeneity in determining response to systemic immunotherapy. Finally, in Aim 3, we will study tumors collected at the time of disease progression in patients treated with immune checkpoint inhibitors to determine whether pre-existent drug resistant clones were present in morphologically heterogeneous primary tumors and that these less immunogenic cancer cells are a basis for drug resistance and disease progression in patients with morphologically heterogeneous tumors. The long-term translational objective will be to use the biologic insights gained to develop improved biomarkers of immunotherapy sensitivity and resistance, and to develop rational immune-based combination strategies that prevent or delay the emergence of drug resistant clones.

 
427
Projects
USD 228.6 M
Aggregated funding amount
USD 689 K
Average funding amount
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
Investigating underlying molecular mechanisms of epigenetic therapies in muscle-invasive bladder cancer

Bladder Cancer Advocacy Network to Swathi Ramakrishnan

USD 1,700
2019 - 2019
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
Role of Fgfr2 signaling in bladder injury and regeneration

National Institute of Diabetes and Digestive and Kidney Diseases to CARLTON MATTHEW BATES

USD 234,750
2019 - 2022
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Targeting FGF in Bladder cancer after Neoadjuvant Immunotherapy and Surgery

American Association For Cancer Research to Joshua James Meeks

USD 25,000
2019 - 2020
Project list item
Refined phenotyping and personalized targeting of muscle-invasive bladder cancer

Swiss National Science Foundation to Roland Seiler, Kiu Yan Charlotte Ng, Eugenio Zoni, Marianna Kruithof-de Julio, Martina Minoli, Franziska Singer, Federico La Manna, Vera Genitsch

USD 702,564
2019 - 2023
Project list item
Identifying Immunological Basis for Bladder Cancer Sex Bias

Canadian Institutes of Health Research to Hyunwoo Kwon, Zihai Li

USD 26,219
2019 - 2022
Project list item
[Development of cancer immunotherapy for urothelial carcinoma targeting tissue infiltrating regulatory T cells] - Original in Japanese

Japan Society for the Promotion of Science to Atsunari Kawashima, 尚 和田, Norio NONOMURA

USD 39,526
2019 - 2022
Project list item
[Novel therapeutic strategy for canine urothelial carcinoma: cancer elimination by anti-inflammation with BRAF inhibitor] - Original in Japanese

Japan Society for the Promotion of Science to 怜平 木之下

USD 39,522
2019 - 2021
Project list item
[Elucidating anticancer drug resistance in urothelial carcinoma by multi-faceted approach] - Original in Japanese

Japan Society for the Promotion of Science to Masayuki NAKAGAWA, Hideki ENOKIDA, 洋一 大迫, Hirofumi YOSHINO

USD 40,720
2019 - 2022
Project list item
New zebrafish-based methods for prediction of cisplatin response in bladder cancer

VINNOVA to Lasse Jensen

USD 33,577
2019 - 2019
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 203,510
2019 - 2021
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 243,205
2019 - 2024
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Specific Inhibition of NOTCH2 Signaling in Bladder Cancer

German Research Foundation to Gerald Bastian Schulz

 
2019 -
Project list item
Clonal evolution and molecular stratification of urothelial carcinoma in situ of the urinary bladder

German Research Foundation to Stefan Garczyk, Nadine Gaisa

 
2019 -
Project list item
The role of a new molecular driver in bladder cancer

National Cancer Institute to DALEY MORERA

USD 45,016
2018 - 2021
load more...